$BCRX
BIOCRYST PHARMACEUTICALS INC Stock $bcrx

$bcrx Overview Financials Valuation SEC Filings Company Website

2024 Q1 Form 10-K Financial Statement

#000162828024007205 Filed on February 27, 2024

Income Statement

Concept	2024 Q1	2023 Q4	2023
Revenue	$92.76M	$93.40M	$331.4M
YoY Change	34.87%	17.42%	22.37%
Cost Of Revenue	$1.265M	$1.637M	$4.481M
YoY Change	34.86%	-34.42%	-30.07%
Gross Profit	$91.50M	$91.76M	$326.9M
YoY Change	34.87%	19.1%	23.64%
Gross Profit Margin	98.64%	98.25%	98.65%
Selling, General & Admin	$59.36M	$64.38M	$213.9M
YoY Change	24.02%	28.37%	34.21%
% of Gross Profit	64.88%	70.16%	65.42%
Research & Development	$46.49M	$70.05M	$216.6M
YoY Change	-3.92%	-4.31%	-14.5%
% of Gross Profit	50.81%	76.34%	66.24%
Depreciation & Amortization	$306.0K	$423.0K	$1.655M
YoY Change	-24.44%	6.82%	15.17%
% of Gross Profit	0.33%	0.46%	0.51%
Operating Expenses	$105.9M	$134.4M	$430.5M
YoY Change	9.98%	8.98%	4.31%
Operating Profit	-$14.49M	-$42.67M	-$103.7M
YoY Change	-49.01%	-7.86%	-30.13%
Interest Expense	$24.51M	-$20.49M	$108.2M
YoY Change	-201.07%	-18.53%	9.23%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income	-$35.01M	-$63.16M	-$226.2M
YoY Change	-33.51%	-11.62%	-7.43%
Income Tax	$365.0K	-$1.431M	$310.0K
% Of Pretax Income
Net Earnings	-$35.38M	-$61.73M	-$226.5M
YoY Change	-33.66%	-13.71%	-8.33%
Net Earnings / Revenue	-38.14%	-66.09%	-68.36%
Basic Earnings Per Share	-$0.17		-$1.18
Diluted Earnings Per Share	-$0.17	-$0.31	-$1.18
COMMON SHARES
Basic Shares Outstanding	206.1M shares	204.8M shares	192.2M shares
Diluted Shares Outstanding	206.1M shares		192.2M shares

Balance Sheet

Concept	2024 Q1	2023 Q4	2023
SHORT-TERM ASSETS
Cash & Short-Term Investments	$336.6M	$389.0M	$389.0M
YoY Change	-15.47%	-8.32%	-8.32%
Cash & Equivalents	$84.33M	$110.6M	$110.6M
Short-Term Investments	$252.2M	$278.3M	$278.3M
Other Short-Term Assets	$20.18M	$21.35M	$21.35M
YoY Change	21.41%	51.84%	51.84%
Inventory	$29.78M	$28.68M	$28.68M
Prepaid Expenses
Receivables	$60.59M	$56.95M	$56.95M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$447.1M	$496.0M	$496.0M
YoY Change	-8.92%	-3.98%	-3.98%
LONG-TERM ASSETS
Property, Plant & Equipment	$7.831M	$7.910M	$20.91M
YoY Change	-6.51%	-8.2%	35.6%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments		$0.00	$0.00
YoY Change		-100.0%	-100.0%
Other Assets	$12.96M	$13.08M	$80.00K
YoY Change	83.95%	92.24%
Total Long-Term Assets	$20.79M	$20.99M	$20.99M
YoY Change	10.28%	-37.33%	-37.33%
TOTAL ASSETS
Total Short-Term Assets	$447.1M	$496.0M	$496.0M
Total Long-Term Assets	$20.79M	$20.99M	$20.99M
Total Assets	$467.9M	$517.0M	$517.0M
YoY Change	-8.21%	-6.01%	-6.01%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$11.91M	$20.89M	$20.89M
YoY Change	90.44%	45.53%	45.53%
Accrued Expenses	$79.25M	$102.9M	$103.9M
YoY Change	5.37%	17.49%	15.57%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$27.66M	$25.16M	$25.16M
YoY Change
Total Short-Term Liabilities	$119.9M	$150.0M	$150.0M
YoY Change	40.82%	42.15%	42.15%
LONG-TERM LIABILITIES
Long-Term Debt	$308.5M	$303.2M	$814.1M
YoY Change	32.67%	30.92%	11.02%
Other Long-Term Liabilities	$8.596M	$8.390M	$8.390M
YoY Change	44.86%	44.56%	44.56%
Total Long-Term Liabilities	$308.5M	$303.2M	$822.5M
YoY Change	32.67%	30.92%	11.29%
TOTAL LIABILITIES
Total Short-Term Liabilities	$119.9M	$150.0M	$150.0M
Total Long-Term Liabilities	$308.5M	$303.2M	$822.5M
Total Liabilities	$428.4M	$453.2M	$972.5M
YoY Change	34.85%	34.43%	15.14%
SHAREHOLDERS EQUITY
Retained Earnings	-$1.717B	-$1.681B
YoY Change	13.83%	15.57%
Common Stock	$2.063M	$2.058M
YoY Change	9.21%	9.53%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$476.2M	-$455.5M	-$455.5M
YoY Change
Total Liabilities & Shareholders Equity	$467.9M	$517.0M	$517.0M
YoY Change	-8.21%	-6.01%	-6.01%

Cashflow Statement

Concept	2024 Q1	2023 Q4	2023
OPERATING ACTIVITIES
Net Income	-$35.38M	-$61.73M	-$226.5M
YoY Change	-33.66%	-13.71%	-8.33%
Depreciation, Depletion And Amortization	$306.0K	$423.0K	$1.655M
YoY Change	-24.44%	6.82%	15.17%
Cash From Operating Activities	-$53.68M	-$8.918M	-$95.14M
YoY Change	12.99%	-62.61%	-41.22%
INVESTING ACTIVITIES
Capital Expenditures	$235.0K	$554.0K	$2.168M
YoY Change	46.88%	5.32%	60.47%
Acquisitions
YoY Change
Other Investing Activities	$28.99M	-$27.92M	-$129.3M
YoY Change	-127.11%	-135.91%	1.93%
Cash From Investing Activities	$28.76M	-$28.47M	-$131.5M
YoY Change	-126.85%	-136.87%	2.54%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$0.00
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-$1.048M	-3.173M	$32.49M
YoY Change	-120.64%	-175.57%	-63.1%
NET CHANGE
Cash From Operating Activities	-$53.68M	-8.918M	-$95.14M
Cash From Investing Activities	$28.76M	-28.47M	-$131.5M
Cash From Financing Activities	-$1.048M	-3.173M	$32.49M
Net Change In Cash	-$26.32M	-40.56M	-$193.8M
YoY Change	-82.41%	-170.47%	-3.82%
FREE CASH FLOW
Cash From Operating Activities	-$53.68M	-$8.918M	-$95.14M
Capital Expenditures	$235.0K	$554.0K	$2.168M
Free Cash Flow	-$53.92M	-$9.472M	-$97.31M
YoY Change	13.1%	-61.14%	-40.37%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023	us-gaap	Interest Expense InterestExpense	108239000	usd
CY2021	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	55838000	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-226229000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-244383000	usd
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-181809000	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	2733000	usd
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	2253000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-184062000	usd
CY2023	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	6095000	usd
CY2022	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	21470000	usd
CY2023	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	1450000	usd
CY2023Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	6449000	usd
CY2022Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	8906000	usd
CY2023Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	17591000	usd
CY2022Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	14990000	usd
CY2023Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	6242000	usd
CY2022Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	4814000	usd
CY2023Q4	us-gaap	Inventory Gross InventoryGross	30282000	usd
CY2022Q4	us-gaap	Inventory Gross InventoryGross	28710000	usd
CY2023Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	1599000	usd
CY2022Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	1177000	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	28683000	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	27533000	usd
CY2023	dei	Entity Central Index Key EntityCentralIndexKey	0000882796
CY2023	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2023	dei	Amendment Flag AmendmentFlag	false
CY2023	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2023Q4	us-gaap	Debt Securities Available For Sale Accrued Interest After Allowance For Credit Loss Statement Of Financial Position Extensible List DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2023#AvailableForSaleSecuritiesDebtSecuritiesCurrent http://fasb.org/us-gaap/2023#LongTermInvestments
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset Statement Of Financial Position Extensible List OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2023#OtherAssetsNoncurrent
CY2022Q4	us-gaap	Debt Securities Available For Sale Accrued Interest After Allowance For Credit Loss Statement Of Financial Position Extensible List DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2023#AvailableForSaleSecuritiesDebtSecuritiesCurrent http://fasb.org/us-gaap/2023#LongTermInvestments
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset Statement Of Financial Position Extensible List OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2023#OtherAssetsNoncurrent
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2022Q4	us-gaap	Finance Lease Right Of Use Asset Statement Of Financial Position Extensible List FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2023#OtherAssetsNoncurrent
CY2023Q4	us-gaap	Finance Lease Right Of Use Asset Statement Of Financial Position Extensible List FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2023#OtherAssetsNoncurrent
CY2023	us-gaap	Open Tax Year OpenTaxYear	2018 2019 2020 2021
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023	dei	Document Transition Report DocumentTransitionReport	false
CY2023	dei	Entity File Number EntityFileNumber	000-23186
CY2023	dei	Entity Registrant Name EntityRegistrantName	BIOCRYST PHARMACEUTICALS, INC.
CY2023	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2023	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	62-1413174
CY2023	dei	Entity Address Address Line1 EntityAddressAddressLine1	4505 Emperor Blvd., Suite 200
CY2023	dei	Entity Address City Or Town EntityAddressCityOrTown	Durham
CY2023	dei	Entity Address State Or Province EntityAddressStateOrProvince	NC
CY2023	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	27703
CY2023	dei	City Area Code CityAreaCode	919
CY2023	dei	Local Phone Number LocalPhoneNumber	859-1302
CY2023	dei	Security12b Title Security12bTitle	Common Stock, $0.01 par value
CY2023	dei	Trading Symbol TradingSymbol	BCRX
CY2023	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	Yes
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2023	dei	Entity Small Business EntitySmallBusiness	false
CY2023	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	true
CY2023	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2023	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Public Float EntityPublicFloat	1322900797	usd
CY2024Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	206149929	shares
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	110643000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	304767000	usd
CY2023Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	1804000	usd
CY2022Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	1472000	usd
CY2023Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	278344000	usd
CY2022Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	119543000	usd
CY2023Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	56950000	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	50599000	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	28683000	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	27533000	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	19542000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	12586000	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	495966000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	516500000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	7910000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	8617000	usd
CY2023Q4	us-gaap	Long Term Investments LongTermInvestments	0	usd
CY2022Q4	us-gaap	Long Term Investments LongTermInvestments	18077000	usd
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	13084000	usd
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	6806000	usd
CY2023Q4	us-gaap	Assets Assets	516960000	usd
CY2022Q4	us-gaap	Assets Assets	550000000	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	14356000	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	102882000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	87565000	usd
CY2023Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	0	usd
CY2022Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	1224000	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1058000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1516000	usd
CY2023Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	1590000	usd
CY2022Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	853000	usd
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	20893000	usd
CY2023Q4	bcrx	Royalty Financing Obligations Current RoyaltyFinancingObligationsCurrent	23565000	usd
CY2022Q4	bcrx	Royalty Financing Obligations Current RoyaltyFinancingObligationsCurrent	0	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	149988000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	105514000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	8390000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	4027000	usd
CY2023Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	2845000	usd
CY2022Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	1777000	usd
CY2023Q4	bcrx	Royalty Financing Obligations Noncurrent RoyaltyFinancingObligationsNoncurrent	508034000	usd
CY2022Q4	bcrx	Royalty Financing Obligations Noncurrent RoyaltyFinancingObligationsNoncurrent	501655000	usd
CY2023Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	303231000	usd
CY2022Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	231624000	usd
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2023Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	450000000	shares
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	450000000	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	205771000	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	205771000	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	187906000	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	187906000	shares
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	2058000	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	1879000	usd
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	1222236000	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	1158118000	usd
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	1337000	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	26000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1681159000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1454620000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-455528000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-294597000	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	516960000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	550000000	usd
CY2022	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	270827000	usd
CY2021	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	157170000	usd
CY2021	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	7229000	usd
CY2023	bcrx	Royalty Royalty	180000	usd
CY2022	bcrx	Royalty Royalty	186000	usd
CY2021	bcrx	Royalty Royalty	35000	usd
CY2022	us-gaap	Interest Expense InterestExpense	99092000	usd
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-103709000	usd
CY2023	bcrx	Interest And Other Income Loss InterestAndOtherIncomeLoss	15777000	usd
CY2022	bcrx	Interest And Other Income Loss InterestAndOtherIncomeLoss	5127000	usd
CY2021	bcrx	Interest And Other Income Loss InterestAndOtherIncomeLoss	62000	usd
CY2021	us-gaap	Interest Expense InterestExpense	59294000	usd
CY2023	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-29019000	usd
CY2022	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	usd
CY2023	us-gaap	Gain Loss On Foreign Currency Derivative Instruments Not Designated As Hedging Instruments GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments	-1039000	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	310000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-226539000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-247116000	usd
CY2023	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	180000	usd
CY2022	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	890000	usd
CY2021	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	189000	usd
CY2023	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	1131000	usd
CY2022	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-1041000	usd
CY2021	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-15000	usd
CY2023	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-225228000	usd
CY2022	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-247267000	usd
CY2021	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-183888000	usd
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.18
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.18
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.33
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.33
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.03
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.03
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	192198000	shares
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	192198000	shares
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	185908000	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	185908000	shares
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	179117000	shares
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	179117000	shares
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-226539000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-247116000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-184062000	usd
CY2023	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1655000	usd
CY2022	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1437000	usd
CY2021	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	777000	usd
CY2023	us-gaap	Inventory Write Down InventoryWriteDown	422000	usd
CY2022	us-gaap	Inventory Write Down InventoryWriteDown	932000	usd
CY2021	us-gaap	Inventory Write Down InventoryWriteDown	0	usd
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	55615000	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	44701000	usd
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	34640000	usd
CY2023	bcrx	Non Cash Interest Expense On Royalty Financing Obligations And Secured Term Loan And Amortization Of Debt Issuance Costs NonCashInterestExpenseOnRoyaltyFinancingObligationsAndSecuredTermLoanAndAmortizationOfDebtIssuanceCosts	85803000	usd
CY2022	bcrx	Non Cash Interest Expense On Royalty Financing Obligations And Secured Term Loan And Amortization Of Debt Issuance Costs NonCashInterestExpenseOnRoyaltyFinancingObligationsAndSecuredTermLoanAndAmortizationOfDebtIssuanceCosts	98918000	usd
CY2021	bcrx	Non Cash Interest Expense On Royalty Financing Obligations And Secured Term Loan And Amortization Of Debt Issuance Costs NonCashInterestExpenseOnRoyaltyFinancingObligationsAndSecuredTermLoanAndAmortizationOfDebtIssuanceCosts	54204000	usd
CY2023	bcrx	Amortization Of Premium Discount On Investments AmortizationOfPremiumDiscountOnInvestments	-10263000	usd
CY2022	bcrx	Amortization Of Premium Discount On Investments AmortizationOfPremiumDiscountOnInvestments	-1777000	usd
CY2021	bcrx	Amortization Of Premium Discount On Investments AmortizationOfPremiumDiscountOnInvestments	-2000	usd
CY2023	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-29019000	usd
CY2022	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	usd
CY2021	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	55838000	usd
CY2023	us-gaap	Tangible Asset Impairment Charges TangibleAssetImpairmentCharges	1548000	usd
CY2022	us-gaap	Tangible Asset Impairment Charges TangibleAssetImpairmentCharges	0	usd
CY2021	us-gaap	Tangible Asset Impairment Charges TangibleAssetImpairmentCharges	0	usd
CY2021	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	20817000	usd
CY2022	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	12423000	usd
CY2021	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	8767000	usd
CY2023	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	6820000	usd
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	2583000	usd
CY2021	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	7155000	usd
CY2023	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-16806000	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-22360000	usd
CY2021	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	39412000	usd
CY2023	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	0	usd
CY2022	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	0	usd
CY2021	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	4168000	usd
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-142157000	usd
CY2022	us-gaap	Payments To Acquire Productive Assets PaymentsToAcquireProductiveAssets	1351000	usd
CY2021	us-gaap	Payments To Acquire Productive Assets PaymentsToAcquireProductiveAssets	2385000	usd
CY2023	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	514407000	usd
CY2022	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	244283000	usd
CY2021	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	10012000	usd
CY2023	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	385077000	usd
CY2022	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	117396000	usd
CY2021	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	28201000	usd
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-131498000	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-128238000	usd
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	15804000	usd
CY2023	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	usd
CY2022	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	usd
CY2021	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	50000000	usd
CY2023	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	8340000	usd
CY2022	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	14765000	usd
CY2021	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	15734000	usd
CY2023	bcrx	Proceeds From Issuance Of Common Stock Issued For Services ProceedsFromIssuanceOfCommonStockIssuedForServices	342000	usd
CY2022	bcrx	Proceeds From Issuance Of Common Stock Issued For Services ProceedsFromIssuanceOfCommonStockIssuedForServices	190000	usd
CY2021	bcrx	Proceeds From Issuance Of Common Stock Issued For Services ProceedsFromIssuanceOfCommonStockIssuedForServices	60000	usd
CY2023	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	2172000	usd
CY2022	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	0	usd
CY2021	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	0	usd
CY2023	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	300000000	usd
CY2022	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	73072000	usd
CY2021	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	0	usd
CY2023	us-gaap	Repayments Of Secured Debt RepaymentsOfSecuredDebt	240452000	usd
CY2022	us-gaap	Repayments Of Secured Debt RepaymentsOfSecuredDebt	0	usd
CY2021	us-gaap	Repayments Of Secured Debt RepaymentsOfSecuredDebt	0	usd
CY2023	us-gaap	Payments Of Loan Costs PaymentsOfLoanCosts	21261000	usd
CY2022	us-gaap	Payments Of Loan Costs PaymentsOfLoanCosts	0	usd
CY2021	us-gaap	Payments Of Loan Costs PaymentsOfLoanCosts	0	usd
CY2023	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	11147000	usd
CY2022	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	0	usd
CY2021	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	0	usd
CY2023	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	1165000	usd
CY2022	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	0	usd
CY2021	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	0	usd
CY2023	bcrx	Proceeds From Royalty Financing Obligation ProceedsFromRoyaltyFinancingObligation	0	usd
CY2022	bcrx	Proceeds From Royalty Financing Obligation ProceedsFromRoyaltyFinancingObligation	0	usd
CY2021	bcrx	Proceeds From Royalty Financing Obligation ProceedsFromRoyaltyFinancingObligation	293874000	usd
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	32485000	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	88027000	usd
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	359668000	usd
CY2023	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	362000	usd
CY2022	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	566000	usd
CY2021	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	71000	usd
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-193792000	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-201495000	usd
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	233386000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	306239000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	507734000	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	274348000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	112447000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	306239000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	507734000	usd
CY2023	us-gaap	Interest Paid Net InterestPaidNet	22139000	usd
CY2022	us-gaap	Interest Paid Net InterestPaidNet	0	usd
CY2021	us-gaap	Interest Paid Net InterestPaidNet	900000	usd
CY2023	us-gaap	Income Taxes Paid IncomeTaxesPaid	1434000	usd
CY2022	us-gaap	Income Taxes Paid IncomeTaxesPaid	3542000	usd
CY2021	us-gaap	Income Taxes Paid IncomeTaxesPaid	118000	usd
CY2023	bcrx	Withholding Taxes Accrued WithholdingTaxesAccrued	4199000	usd
CY2022	bcrx	Withholding Taxes Accrued WithholdingTaxesAccrued	1990000	usd
CY2021	bcrx	Withholding Taxes Accrued WithholdingTaxesAccrued	984000	usd
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	-19262000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-184062000	usd
CY2021	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	174000	usd
CY2021	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	13745000	usd
CY2021	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	1989000	usd
CY2021	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	3846000	shares
CY2021	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	45730000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-106986000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-247116000	usd
CY2022	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-151000	usd
CY2022	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	11900000	usd
CY2022	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	2862000	usd
CY2022	bcrx	Class Of Warrant Or Right Exercised During Period ClassOfWarrantOrRightExercisedDuringPeriod	253000	shares
CY2022	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	3000	usd
CY2022	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	190000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-226539000	usd
CY2023	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	1311000	usd
CY2023	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	1276000	shares
CY2023	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	6114000	usd
CY2023	us-gaap	Shares Paid For Tax Withholding For Share Based Compensation SharesPaidForTaxWithholdingForShareBasedCompensation	59000	shares
CY2023	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	370000	usd
CY2023	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	2596000	usd
CY2023	bcrx	Class Of Warrant Or Right Exercised During Period ClassOfWarrantOrRightExercisedDuringPeriod	14997000	shares
CY2023	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	342000	usd
CY2023	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	55615000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-455528000	usd
CY2023	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. Significant estimates in the Company’s consolidated financial statements have been made relative to the calculation of net product sales, the ORLADEYO and Factor D inhibitors royalty financing obligations, inventory reserves, certain accruals, primarily related to the Company’s research and development expenses, the valuation of stock options and the valuation allowance for deferred tax assets resulting from net operating losses. These estimates are based on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ from those estimates.</span></div>
CY2023	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	331412000	usd
CY2022	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	270827000	usd
CY2021	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	157170000	usd
CY2023	bcrx	Longterm Investment Maturity Minimum LongtermInvestmentMaturityMinimum	P12M
CY2023	us-gaap	Advertising Expense AdvertisingExpense	14404000	usd
CY2022	us-gaap	Advertising Expense AdvertisingExpense	14891000	usd
CY2021	us-gaap	Advertising Expense AdvertisingExpense	5705000	usd
CY2023	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	47539000	shares
CY2022	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	56290000	shares
CY2023	us-gaap	Reclassification From Accumulated Other Comprehensive Income Current Period Before Tax ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax	0	usd
CY2022	us-gaap	Reclassification From Accumulated Other Comprehensive Income Current Period Before Tax ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax	0	usd
CY2021	us-gaap	Reclassification From Accumulated Other Comprehensive Income Current Period Before Tax ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax	1000	usd
CY2023	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	331412000	usd
CY2022	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	270827000	usd
CY2021	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	157170000	usd
CY2023Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	278344000	usd
CY2022Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	137620000	usd
CY2023Q4	us-gaap	Debt Securities Available For Sale Unrealized Loss Position Number Of Positions DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions	11	securities
CY2023Q4	us-gaap	Debt Securities Available For Sale Unrealized Loss Position DebtSecuritiesAvailableForSaleUnrealizedLossPosition	18513000	usd
CY2023Q4	us-gaap	Debt Securities Available For Sale Amortized Cost Excluding Accrued Interest After Allowance For Credit Loss DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss	278131000	usd
CY2023Q4	us-gaap	Debt Securities Available For Sale Accrued Interest After Allowance For Credit Loss DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss	135000	usd
CY2023Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	150000	usd
CY2023Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	72000	usd
CY2023Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	278344000	usd
CY2022Q4	us-gaap	Debt Securities Available For Sale Amortized Cost Excluding Accrued Interest After Allowance For Credit Loss DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss	138196000	usd
CY2022Q4	us-gaap	Debt Securities Available For Sale Accrued Interest After Allowance For Credit Loss DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss	487000	usd
CY2022Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	0	usd
CY2022Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	1063000	usd
CY2022Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	137620000	usd
CY2023Q4	us-gaap	Available For Sale Securities Debt Maturities Within One Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue	278344000	usd
CY2022Q4	us-gaap	Available For Sale Securities Debt Maturities Within One Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue	119543000	usd
CY2023Q4	bcrx	Maturing After One Year Through Two Years MaturingAfterOneYearThroughTwoYears	0	usd
CY2022Q4	bcrx	Maturing After One Year Through Two Years MaturingAfterOneYearThroughTwoYears	18077000	usd
CY2023Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	278344000	usd
CY2022Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	137620000	usd
CY2023Q4	us-gaap	Receivables Net Current ReceivablesNetCurrent	2296000	usd
CY2022Q4	us-gaap	Receivables Net Current ReceivablesNetCurrent	8268000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	19120000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	18167000	usd
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	11210000	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	9550000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	7910000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	8617000	usd
CY2023	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1655000	usd
CY2022	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1437000	usd
CY2021	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	777000	usd
CY2023	us-gaap	Tangible Asset Impairment Charges TangibleAssetImpairmentCharges	1548000	usd
CY2023	us-gaap	Loss On Contract Termination LossOnContractTermination	440000	usd
CY2022	us-gaap	Tangible Asset Impairment Charges TangibleAssetImpairmentCharges	0	usd
CY2021	us-gaap	Tangible Asset Impairment Charges TangibleAssetImpairmentCharges	0	usd
CY2023Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	36518000	usd
CY2022Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	22125000	usd
CY2023Q4	bcrx	Revenue Related Reserves For Discounts And Allowances RevenueRelatedReservesForDiscountsAndAllowances	26509000	usd
CY2022Q4	bcrx	Revenue Related Reserves For Discounts And Allowances RevenueRelatedReservesForDiscountsAndAllowances	14332000	usd
CY2023Q4	bcrx	Royalties Payable RoyaltiesPayable	18524000	usd
CY2022Q4	bcrx	Royalties Payable RoyaltiesPayable	7700000	usd
CY2023Q4	bcrx	Accrued Development Costs AccruedDevelopmentCosts	13677000	usd
CY2022Q4	bcrx	Accrued Development Costs AccruedDevelopmentCosts	30360000	usd
CY2023Q4	bcrx	Accrued Inventory Expense AccruedInventoryExpense	190000	usd
CY2022Q4	bcrx	Accrued Inventory Expense AccruedInventoryExpense	4193000	usd
CY2023Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	7464000	usd
CY2022Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	8855000	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	102882000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	87565000	usd
CY2020Q4	bcrx	Future Royalties Payable FutureRoyaltiesPayable	124717000	usd
CY2021Q4	us-gaap	Long Term Debt LongTermDebt	298142000	usd
CY2021	bcrx	Non Cash Interest Expense On Royalty Financing Obligation NonCashInterestExpenseOnRoyaltyFinancingObligation	37670000	usd
CY2021	bcrx	Royalties Revenues Paid And Payable RoyaltiesRevenuesPaidAndPayable	-11154000	usd
CY2021Q4	bcrx	Future Royalties Payable FutureRoyaltiesPayable	449375000	usd
CY2022	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	34000	usd
CY2022	bcrx	Non Cash Interest Expense On Royalty Financing Obligation NonCashInterestExpenseOnRoyaltyFinancingObligation	76482000	usd
CY2022	bcrx	Royalties Revenues Paid And Payable RoyaltiesRevenuesPaidAndPayable	-24168000	usd
CY2022Q4	bcrx	Future Royalties Payable FutureRoyaltiesPayable	501655000	usd
CY2023	bcrx	Non Cash Interest Expense On Royalty Financing Obligation NonCashInterestExpenseOnRoyaltyFinancingObligation	70356000	usd
CY2023	bcrx	Royalties Revenues Paid And Payable RoyaltiesRevenuesPaidAndPayable	-40412000	usd
CY2023Q4	bcrx	Future Royalties Payable FutureRoyaltiesPayable	531599000	usd
CY2023	us-gaap	Operating Lease Expense OperatingLeaseExpense	2018000	usd
CY2022	us-gaap	Operating Lease Expense OperatingLeaseExpense	1578000	usd
CY2021	us-gaap	Operating Lease Expense OperatingLeaseExpense	1660000	usd
CY2023	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	1212000	usd
CY2022	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	816000	usd
CY2021	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	113000	usd
CY2023	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	201000	usd
CY2022	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	138000	usd
CY2021	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	22000	usd
CY2023	bcrx	Financing Lease Expense FinancingLeaseExpense	1413000	usd
CY2022	bcrx	Financing Lease Expense FinancingLeaseExpense	954000	usd
CY2021	bcrx	Financing Lease Expense FinancingLeaseExpense	135000	usd
CY2023Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P9Y8M12D
CY2022Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P10Y7M6D
CY2023Q4	us-gaap	Finance Lease Weighted Average Remaining Lease Term1 FinanceLeaseWeightedAverageRemainingLeaseTerm1	P3Y
CY2022Q4	us-gaap	Finance Lease Weighted Average Remaining Lease Term1 FinanceLeaseWeightedAverageRemainingLeaseTerm1	P3Y
CY2023Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.1088
CY2022Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.1254
CY2023Q4	us-gaap	Finance Lease Weighted Average Discount Rate Percent FinanceLeaseWeightedAverageDiscountRatePercent	0.0746
CY2022Q4	us-gaap	Finance Lease Weighted Average Discount Rate Percent FinanceLeaseWeightedAverageDiscountRatePercent	0.0500
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	8682000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	4242000	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1058000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1516000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	8390000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	4027000	usd
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	9448000	usd
CY2023Q4	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	4322000	usd
CY2022Q4	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	2564000	usd
CY2023Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	1590000	usd
CY2022Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	853000	usd
CY2023Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	2845000	usd
CY2022Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	1777000	usd
CY2023Q4	us-gaap	Finance Lease Liability FinanceLeaseLiability	4435000	usd
CY2022Q4	us-gaap	Finance Lease Liability FinanceLeaseLiability	2630000	usd
CY2023Q4	bcrx	Operating Lease Right Of Use Asset Accumulated Amortization OperatingLeaseRightOfUseAssetAccumulatedAmortization	4794000	usd
CY2022Q4	bcrx	Operating Lease Right Of Use Asset Accumulated Amortization OperatingLeaseRightOfUseAssetAccumulatedAmortization	3268000	usd
CY2023Q4	us-gaap	Finance Lease Right Of Use Asset Accumulated Amortization FinanceLeaseRightOfUseAssetAccumulatedAmortization	2293000	usd
CY2022Q4	us-gaap	Finance Lease Right Of Use Asset Accumulated Amortization FinanceLeaseRightOfUseAssetAccumulatedAmortization	1081000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	2014000	usd
CY2023Q4	us-gaap	Finance Lease Liability Payments Due Next Twelve Months FinanceLeaseLiabilityPaymentsDueNextTwelveMonths	1857000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	1701000	usd
CY2023Q4	us-gaap	Finance Lease Liability Payments Due Year Two FinanceLeaseLiabilityPaymentsDueYearTwo	1732000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	1509000	usd
CY2023Q4	us-gaap	Finance Lease Liability Payments Due Year Three FinanceLeaseLiabilityPaymentsDueYearThree	899000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	1463000	usd
CY2023Q4	us-gaap	Finance Lease Liability Payments Due Year Four FinanceLeaseLiabilityPaymentsDueYearFour	437000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	1312000	usd
CY2023Q4	us-gaap	Finance Lease Liability Payments Due Year Five FinanceLeaseLiabilityPaymentsDueYearFive	27000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	7952000	usd
CY2023Q4	us-gaap	Finance Lease Liability Payments Due After Year Five FinanceLeaseLiabilityPaymentsDueAfterYearFive	0	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	15951000	usd
CY2023Q4	us-gaap	Finance Lease Liability Payments Due FinanceLeaseLiabilityPaymentsDue	4952000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	6503000	usd
CY2023Q4	us-gaap	Finance Lease Liability Undiscounted Excess Amount FinanceLeaseLiabilityUndiscountedExcessAmount	517000	usd
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	9448000	usd
CY2023Q4	us-gaap	Finance Lease Liability FinanceLeaseLiability	4435000	usd
CY2023	us-gaap	Finance Lease Interest Payment On Liability FinanceLeaseInterestPaymentOnLiability	201000	usd
CY2022	us-gaap	Finance Lease Interest Payment On Liability FinanceLeaseInterestPaymentOnLiability	898000	usd
CY2021	us-gaap	Finance Lease Interest Payment On Liability FinanceLeaseInterestPaymentOnLiability	125000	usd
CY2023	us-gaap	Operating Lease Payments OperatingLeasePayments	1920000	usd
CY2022	us-gaap	Operating Lease Payments OperatingLeasePayments	1555000	usd
CY2021	us-gaap	Operating Lease Payments OperatingLeasePayments	1490000	usd
CY2023	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	1165000	usd
CY2022	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	0	usd
CY2021	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	0	usd
CY2023	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	4695000	usd
CY2022	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	755000	usd
CY2021	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	1536000	usd
CY2023	us-gaap	Right Of Use Asset Obtained In Exchange For Finance Lease Liability RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability	2971000	usd
CY2022	us-gaap	Right Of Use Asset Obtained In Exchange For Finance Lease Liability RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability	1302000	usd
CY2021	us-gaap	Right Of Use Asset Obtained In Exchange For Finance Lease Liability RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability	2190000	usd
CY2023	bcrx	Non Cash Increase In Operating Lease Assets Due To Remeasurement Of Operating Lease Liabilities NonCashIncreaseInOperatingLeaseAssetsDueToRemeasurementOfOperatingLeaseLiabilities	924000	usd
CY2022	bcrx	Non Cash Increase In Operating Lease Assets Due To Remeasurement Of Operating Lease Liabilities NonCashIncreaseInOperatingLeaseAssetsDueToRemeasurementOfOperatingLeaseLiabilities	0	usd
CY2021	bcrx	Non Cash Increase In Operating Lease Assets Due To Remeasurement Of Operating Lease Liabilities NonCashIncreaseInOperatingLeaseAssetsDueToRemeasurementOfOperatingLeaseLiabilities	0	usd
CY2023Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	58020000	shares
CY2022Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	67235000	shares
CY2023Q4	bcrx	Share Based Payment Arrangement Number Of Plans ShareBasedPaymentArrangementNumberOfPlans	3	plan
CY2023	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	55615000	usd
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	44701000	usd
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	34640000	usd
CY2023	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	55615000	usd
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	44701000	usd
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	34640000	usd
CY2023	us-gaap	Stock Issued During Period Shares Employee Stock Purchase Plans StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans	338000	shares
CY2022	us-gaap	Stock Issued During Period Shares Employee Stock Purchase Plans StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans	260000	shares
CY2021	us-gaap	Stock Issued During Period Shares Employee Stock Purchase Plans StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans	321000	shares
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-206674000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-225127000	usd
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-159632000	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-19555000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-19256000	usd
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-22177000	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-226229000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-244383000	usd
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-181809000	usd
CY2023	us-gaap	Current Federal State And Local Tax Expense Benefit CurrentFederalStateAndLocalTaxExpenseBenefit	-45000	usd
CY2022	us-gaap	Current Federal State And Local Tax Expense Benefit CurrentFederalStateAndLocalTaxExpenseBenefit	2430000	usd
CY2021	us-gaap	Current Federal State And Local Tax Expense Benefit CurrentFederalStateAndLocalTaxExpenseBenefit	2179000	usd
CY2023	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	1037000	usd
CY2022	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	292000	usd
CY2021	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	233000	usd
CY2023	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	992000	usd
CY2022	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	2722000	usd
CY2021	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	2412000	usd
CY2023	us-gaap	Deferred Federal State And Local Tax Expense Benefit DeferredFederalStateAndLocalTaxExpenseBenefit	-120000	usd
CY2022	us-gaap	Deferred Federal State And Local Tax Expense Benefit DeferredFederalStateAndLocalTaxExpenseBenefit	11000	usd
CY2021	us-gaap	Deferred Federal State And Local Tax Expense Benefit DeferredFederalStateAndLocalTaxExpenseBenefit	-159000	usd
CY2023	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	-562000	usd
CY2022	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	0	usd
CY2021	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	0	usd
CY2023	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-682000	usd
CY2022	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	11000	usd
CY2021	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-159000	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	310000	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	2733000	usd
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	2253000	usd
CY2023	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21
CY2021	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21
CY2023	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-47328000	usd
CY2022	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-51321000	usd
CY2021	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-38175000	usd
CY2023	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-3477000	usd
CY2022	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-1816000	usd
CY2021	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-2288000	usd
CY2023	us-gaap	Income Tax Reconciliation Nondeductible Expense IncomeTaxReconciliationNondeductibleExpense	3015000	usd
CY2022	us-gaap	Income Tax Reconciliation Nondeductible Expense IncomeTaxReconciliationNondeductibleExpense	-1608000	usd
CY2021	us-gaap	Income Tax Reconciliation Nondeductible Expense IncomeTaxReconciliationNondeductibleExpense	-1343000	usd
CY2023	bcrx	Income Tax Reconciliation Income Tax Expense Benefit Expiration Of Carry Forwards IncomeTaxReconciliationIncomeTaxExpenseBenefitExpirationOfCarryForwards	0	usd
CY2022	bcrx	Income Tax Reconciliation Income Tax Expense Benefit Expiration Of Carry Forwards IncomeTaxReconciliationIncomeTaxExpenseBenefitExpirationOfCarryForwards	0	usd
CY2021	bcrx	Income Tax Reconciliation Income Tax Expense Benefit Expiration Of Carry Forwards IncomeTaxReconciliationIncomeTaxExpenseBenefitExpirationOfCarryForwards	-1057000	usd
CY2023	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	3301000	usd
CY2022	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	9793000	usd
CY2021	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	5994000	usd
CY2023	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	2255000	usd
CY2022	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	1862000	usd
CY2021	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	1940000	usd
CY2023	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	1656000	usd
CY2022	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	-5485000	usd
CY2021	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	1216000	usd
CY2023	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	47490000	usd
CY2022	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	70894000	usd
CY2021	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	47954000	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	310000	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	2733000	usd
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	2253000	usd
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	13844000	usd
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	9729000	usd
CY2023	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	825000	usd
CY2022	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	4115000	usd
CY2023	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	307000	usd
CY2022	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	0	usd
CY2023Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	14362000	usd
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	13844000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Domestic DeferredTaxAssetsOperatingLossCarryforwardsDomestic	108753000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Domestic DeferredTaxAssetsOperatingLossCarryforwardsDomestic	101600000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	88390000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	86321000	usd
CY2023Q4	bcrx	Deferred Tax Assets Royalty Income DeferredTaxAssetsRoyaltyIncome	122391000	usd
CY2022Q4	bcrx	Deferred Tax Assets Royalty Income DeferredTaxAssetsRoyaltyIncome	115554000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	26113000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	19374000	usd
CY2023Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	75081000	usd
CY2022Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	62794000	usd
CY2023Q4	bcrx	Deferred Tax Assets Leasing Obligations DeferredTaxAssetsLeasingObligations	3076000	usd
CY2022Q4	bcrx	Deferred Tax Assets Leasing Obligations DeferredTaxAssetsLeasingObligations	1842000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	17515000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	4354000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	441319000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	391839000	usd
CY2023Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	678000	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	717000	usd
CY2023Q4	bcrx	Deferred Tax Liabilities Right Of Use Assets DeferredTaxLiabilitiesRightOfUseAssets	2872000	usd
CY2022Q4	bcrx	Deferred Tax Liabilities Right Of Use Assets DeferredTaxLiabilitiesRightOfUseAssets	1525000	usd
CY2023Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	3550000	usd
CY2022Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	2242000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	437098000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	389608000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	671000	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	11000	usd
CY2023	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	47490000	usd
CY2022	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	70894000	usd
CY2021	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	47954000	usd
CY2021Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	0	usd
CY2023Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	0	usd
CY2022Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	0	usd
CY2023	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	5716000	usd
CY2022	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	3758000	usd
CY2021	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	2834000	usd
CY2023	dei	Auditor Name AuditorName	Ernst & Young LLP
CY2023	dei	Auditor Location AuditorLocation	Raleigh, NC
CY2023	dei	Auditor Name AuditorName	Ernst & Young LLP
CY2023	dei	Auditor Location AuditorLocation	Raleigh, NC
CY2023Q4	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2023Q4	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2023Q4	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	true
CY2023Q4	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false
CY2023	dei	Auditor Firm AuditorFirmId	42

Files In Submission

Name	View Source	Status
0001628280-24-007205-index-headers.html	Edgar Link	pending
0001628280-24-007205-index.html	Edgar Link	pending
0001628280-24-007205.txt	Edgar Link	pending
0001628280-24-007205-xbrl.zip	Edgar Link	pending
bcrx-20231231.htm	Edgar Link	pending
bcrx-20231231.xsd	Edgar Link	pending
bcrx-20231231xex311.htm	Edgar Link	pending
bcrx-20231231xex312.htm	Edgar Link	pending
bcrx-20231231xex321.htm	Edgar Link	pending
bcrx-20231231xex322.htm	Edgar Link	pending
bcrx-20231231_g1.jpg	Edgar Link	pending
exhibit21-subsidiaries1.htm	Edgar Link	pending
bcrx-20231231_def.xml	Edgar Link	unprocessable
bcrx-20231231_lab.xml	Edgar Link	unprocessable
bcrx-20231231_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
exhibit23-202310xkxdraftco.htm	Edgar Link	pending
exhibit97-nasdaqcompliantc.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R81.htm	Edgar Link	pending
R82.htm	Edgar Link	pending
R83.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
bcrx-20231231_cal.xml	Edgar Link	unprocessable
bcrx-20231231_htm.xml	Edgar Link	completed

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$BCRX
BIOCRYST PHARMACEUTICALS INC Stock $bcrx

2024 Q1 Form 10-K Financial Statement

#000162828024007205 Filed on February 27, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$BCRX BIOCRYST PHARMACEUTICALS INC Stock $bcrx

2024 Q1 Form 10-K Financial Statement

#000162828024007205 Filed on February 27, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$BCRX
BIOCRYST PHARMACEUTICALS INC Stock $bcrx